BioRestorative Therapies' CEO to Speak at ROTH Conference
BioRestorative Therapies' CEO to Address Investment Opportunities
BioRestorative Therapies, Inc. (NASDAQ: BRTX), a leader in regenerative medicine, will have its Chief Executive Officer, Lance Alstodt, present at the 3rd Annual ROTH Healthcare Opportunities Conference. Set for October 9, 2024, this event will provide a platform for direct interaction between BioRestorative and potential investors.
Engagement Through One-on-One Meetings
The conference emphasizes personalized interactions, featuring a series of one-on-one investor meetings designed to facilitate discussions. Investors interested in scheduling a meeting with BioRestorative are encouraged to reach out to their ROTH MKM sales representatives to arrange these connections.
Discover BioRestorative Therapies' Innovative Solutions
Founded with a vision to advance the field of regenerative medicine, BioRestorative Therapies is dedicated to developing therapeutic products through innovative cell and tissue protocols. The company primarily focuses on adult stem cells, with two core clinical development programs in the areas of chronic pain and metabolic disorders.
Overview of Key Programs
BioRestorative's first critical initiative, known as brtxDISC™, showcases its lead cell therapy candidate, BRTX-100. This product leverages a patient’s own cultured mesenchymal stem cells, which are harvested from bone marrow, to potentially treat painful lumbosacral disc disorders without the need for invasive surgery. Through a careful process involving the isolation and cryopreservation of these stem cells, BRTX-100 represents a significant innovation in non-surgical treatment methods.
Addressing Metabolic Disorders
The second program, ThermoStem®, is another exciting venture, where BioRestorative aims to tackle obesity and related metabolic disorders. Their research utilizes brown adipose-derived stem cells (BADSC) to create brown adipose tissue (BAT), which has shown promise in enhancing calorie burning and regulating metabolic processes. In early studies, increased levels of BAT have been linked to healthier metabolic outcomes, including lower risks of obesity and diabetes.
Cosmetic Innovations with BioCosmeceuticals
In addition to its medical therapies, BioRestorative Therapies is expanding into the cosmetic industry with its BioCosmeceuticals line. The company recently launched a cell-based secretome serum designed to combat signs of aging, such as fine lines and wrinkles. This product, developed in a state-of-the-art cGMP ISO-7 certified clean room, exemplifies the company's commitment to quality and innovation in aesthetic products.
Future Directions and Research Initiatives
BioRestorative's leadership looks to the future with an excitement for growth in both their therapeutic and cosmetic offerings. The company plans to broaden its range of cell-based products while navigating the pathway to receive U.S. Food and Drug Administration (FDA) approvals for its innovative aesthetic treatments. Such advancements would not only enhance the value of BioRestorative’s portfolio but also signal a shift in how regenerative products can be utilized in both medical and cosmetic fields.
Get in Touch with the Company
For those interested in learning more about BioRestorative Therapies' initiatives or to inquire about potential investment opportunities, the company encourages contact with their Investor Relations team. The designated contact for inquiries is Stephen Kilmer, who can be reached directly at (646) 274-3580 or via email.
Frequently Asked Questions
What is BioRestorative Therapies known for?
BioRestorative Therapies focuses on developing stem cell-based therapeutics, specifically in pain management and metabolic disorders.
Who will represent BioRestorative at the ROTH conference?
CEO Lance Alstodt will represent BioRestorative Therapies at the conference, discussing company innovations and investment opportunities.
What are the main programs BioRestorative is working on?
The main programs include the brtxDISC™ for spine conditions and ThermoStem® for metabolic disorders using stem cell technology.
How do BioRestorative's products work?
Their products utilize a patient’s own stem cells or derived substances to promote healing, treat disorders, and improve cosmetic appearance.
How can investors get in touch with BioRestorative?
Investors can arrange meetings through ROTH MKM sales representatives or contact Investor Relations for more information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Cathie Wood's ARK ETF Makes Bold Moves in Tech Investments
- SCU Receives NIH Grant to Transform Chronic Back Pain Care
- ANZ Agrees to $68 Million Settlement for Class Actions
- Investors Urged to Engage in Allarity Therapeutics Class Action
- Nvidia's Blackwell GPUs Set to Transform the Market Landscape
- Global CBRN Security Market Growth Projections to 2033
- NuLegacy Gold Moves Ahead with Strategic Changes and Financing
- BLG Group and Verona to Revolutionize North American Realty
- Metagenomi, Inc. Shareholders Invited to Join Class Action Lawsuit
- Outcrop Silver Secures $5 Million Financing to Boost Projects
Recent Articles
- IQVentures Acquires Aaron's Company for $504 Million Deal
- American Healthcare REIT Readies for Q3 2024 Earnings Results
- Light & Wonder to Host Q3 2024 Results Conference Call
- Verano Holdings to Announce Q3 2024 Financial Results Soon
- Parsons Corporation Takes Lead in Environmental Technology
- Discover Craftsmanship at the Homestead Heritage Festival
- GeneDx Set to Release Q3 2024 Financial Results Soon
- Kinsale Capital Welcomes New Director to Strengthen Strategy
- Compass Diversified Announces Enhanced Shareholder Distributions
- Sunnova Energy Sets Expectations for Q3 2024 Financial Results
- Iridex Corporation's New CEO to Spearhead Strategic Changes
- Reddit Prepares to Share Q3 2024 Financial Results Soon
- Upcoming Third Quarter Release and Conference by Employers Holdings
- AbbVie Adjusts 2024 Earnings Forecast Amid New Developments
- AgEagle Aerial Systems Joins NATO's REPMUS 2024 Exercise
- Atmos Energy's Upcoming Conference Call for Fiscal Year Review
- Recent Merger Announcement for Martin Midstream Partners
- UMH Properties, Inc. Reports Strong Q3 2024 Growth Milestones
- Trevi Therapeutics Achieves Milestones in Cough Therapy Trials
- Snap Inc. Schedules Conference Call for Financial Insights
- Energy Transfer LP to Announce Q3 2024 Earnings on November 6
- Roblox's CFO Transition: Leadership Change and Future Prospects
- Uniti Group Inc. Set to Reveal Q3 2024 Earnings with Call Details
- Xylem Inc. Plans to Announce Q3 2024 Results Soon
- HomeTrust Bank Aids Communities Affected by Hurricane Helene
- French Prime Minister Barnier's Bold Tax Reforms for Business Growth
- TeraWulf's Strategic Sale to Enhance Bitcoin Mining Operations
- Upcoming Earnings Call for AvalonBay Communities, Inc. Revealed
- Market Insights: Jobs Report and Geopolitical Tensions Affect Stocks
- Kaixin Holdings Achieves Key Shareholder Resolutions for Growth
- Essex Property Trust Set to Announce Q3 2024 Earnings Soon
- Understanding the Impact of Federal Rate Cuts on Investments
- Scott Mendel Named Chairman at Akoya Biosciences Leadership
- MetLife Plans Q3 2024 Earnings Call for Investors
- Abivax Celebrates First Patient Enrollment in Crohn’s Disease Trial
- RenaissanceRe Plans Third Quarter 2024 Financial Call Details
- Middlesex Water Company Celebrated for Innovative Video Recognition
- RGA's Upcoming Earnings Report and Conference Call Overview
- CSX Corporation Releases Details on Latest Dividend Decision
- Impinj Financial Results Announcement for Third Quarter 2024
- Exciting Inducement Grants Announced by Intellia Therapeutics
- COPT Defense Schedules Call to Review Q3 2024 Performance
- Credit Acceptance Ranks Among Top 200 Most Admired Workplaces
- Amundi US Announces Monthly Dividends for Pioneer Funds
- MAX Power Expands Natural Hydrogen Exploration Across Regions
- Hurricane Helene's Impact on MarineMax Operations Discussed
- Iridex Corporation Welcomes Patrick Mercer as New CEO
- Sonida Expands Senior Living Portfolio and Enhances Financing Strategy
- Stay Updated: ResMed's Earnings Report and Webcast Details
- Pebblebrook Hotel Trust Completes $400 Million Senior Notes Deal